TNON vs SIBN

For growth investors, SI-BONE, Inc.

(SIBN) is the stronger pick with 20. 2% revenue growth year-over-year, versus 11. 9% for Tenon Medical, Inc. (TNON). Analysts rate SI-BONE, Inc. (SIBN) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, SI-BONE, Inc.

(SIBN) delivered a total return of -59. 7%, compared to -100. 0% for Tenon Medical, Inc. (TNON). Over 10 years, the gap is even starker: SIBN returned -35. 4% versus TNON's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Tenon Medical, Inc.

(TNON) is the lower-risk stock at 1. 08β versus SI-BONE, Inc. 's 1. 12β — meaning SIBN is approximately 4% more volatile than TNON relative to the S&P 500. On balance sheet safety, SI-BONE, Inc. (SIBN) carries a lower debt/equity ratio of 1% versus 7% for Tenon Medical, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), SI-BONE, Inc.

(SIBN) is pulling ahead at 20. 2% versus 11. 9% for Tenon Medical, Inc. (TNON). On earnings-per-share growth, the picture is similar: Tenon Medical, Inc. grew EPS 83. 6% year-over-year, compared to 41. 3% for SI-BONE, Inc.. Over a 3-year CAGR, TNON leads at 173. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

SI-BONE, Inc.

(SIBN) is the more profitable company, earning -9. 4% net margin versus -417. 2% for Tenon Medical, Inc. — meaning it keeps -9. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SIBN leads at -11. 1% versus -420. 1% for TNON. At the gross margin level — before operating expenses — SIBN leads at 79. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, SI-BONE, Inc.

(SIBN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 12)). Both have compounded well over 10 years (SIBN: -35. 4%, TNON: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TNON is a small-cap quality compounder stock; SIBN is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.